A mathematical framework to determine the temporal sequence of somatic genetic events in cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 41, 2010, Pages 17604-17609

  Attolini, Camille Stephan Otto ^a   Cheng, Yu Kang ^a,b   Beroukhim, Rameen ^c,d,e,f   Getz, Gad ^c   Abdel Wahab, Omar ^a   Levine, Ross L ^a   Mellinghoff, Ingo K ^a   Michor, Franziska ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Mathematical modeling; Optimization algorithm; Stochastic framework

Indexed keywords

APC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53;

ALGORITHM; ARTICLE; CANCER GENETICS; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; GENE MUTATION; GENETIC ANALYSIS; GENOMICS; GLIOBLASTOMA; HUMAN; LEUKEMIA; MATHEMATICAL MODEL; PRIORITY JOURNAL; RETRACING THE EVOLUTIONARY STEPS IN CANCER;

ALGORITHMS; BLOOD COAGULATION FACTORS; COLONIC NEOPLASMS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DISEASE PROGRESSION; GENOMICS; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, CELL SURFACE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78049245056     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009117107     Document Type: Article

References (30)

1. Bamford S, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355-358.
2. Sjöblom T, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
3. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
4. Beroukhim R, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104:20007-20012.
5. Taylor BS, et al. (2008) Functional copy-number alterations in cancer. PLoS ONE 3:e3179.
6. Hartl DL, Clark AG (2007) Principles of Population Genetics (Sinauer Associates, Sunderland, MA), 4th Ed p xv.
7. Moran PAP (1962) The Statistical Processes of Evolutionary Theory (Clarendon Press, Oxford, UK) p 200.
8. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396:643-649.
9. Kunkel TA, Bebenek K (2000) DNA replication fidelity. Annu Rev Biochem 69:497-529.
10. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767.
11. Vogelstein B, Kinzler KW (2002) The Genetic Basis of Human Cancer (McGraw-Hill, New York), 2nd Ed p 821.
12. Buday L, Downward J (2008) Many faces of Ras activation. Biochim Biophys Acta 1786:178-187.
13. McGillicuddy LT (2009) Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16:44-54.
14. Zhu Y, et al. (2005) Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-130.
15. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453. (Pubitemid 47339290)
16. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673-683.
17. Campbell PJ, et al. (2006) Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108:3548-3555.
18. Levine RL, et al. (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107:4139-4141.
19. Delhommeau F, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289-2301.
20. Tefferi A, et al. (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343-1345.
21. Langemeijer SM, et al. (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842.
22. Abdel-Wahab O, et al. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147.
23. Theocharides A, et al. (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110:375-379.
24. Abdel-Wahab O, et al. (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:447-452.
25. Weinstein IB (2002) CANCER: Addiction to oncogenes - the Achilles heal of cancer. Science 297:63-64.
26. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181. (Pubitemid 46316032)
27. Bachoo RM, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
28. Zhu H, et al. (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA 106:2712-2716.
29. Smith G, et al. (2002) Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99:9433-9438.
30. Sharpless NE, Depinho RA (2006) The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754. (Pubitemid 44323701)